

Financial news for PGNX dated on 2020-05-18: Progenics to Present Results from the Phase 3 CONDOR Trial of PyL(tm) (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Financial news for PGNX dated on 2020-05-07: Progenics Pharmaceuticals Q1 EPS \$(0.190) Beats \$(0.220) Estimate, Sales \$6.200M Miss \$7.900M Estimate

Financial news for PGNX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for PGNX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for PGNX dated on 2020-04-14: Lantheus, Progenics Pharma Report Support Deal With Velan Capital Related To Merger

Financial news for PGNX dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for PGNX dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PGNX dated on 2020-03-13: Progenics Pharma Q4 EPS \$(0.13) vs \$(0.17) In Same Qtr. Last Year

Financial news for PGNX dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for PGNX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for PGNX dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for PGNX dated on 2020-02-21: 95 Biggest Movers From Yesterday

Financial news for PGNX dated on 2020-02-20: Lantheus, Progenics Pharma Report Amended Ratio For Deal: Lantheus Stock Term Raised From 0.2502 Lantheus Share To 0.31

Financial news for PGNX dated on 2020-01-21: Progenics Pharmaceuticals Provides Update On Reconstituted Board's Ongoing Strategic Review

Financial news for PGNX dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for PGNX dated on 2019-12-24: 78 Biggest Movers From Yesterday

Financial news for PGNX dated on 2019-12-23: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for PGNX dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for PGNX dated on 2019-12-23: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for PGNX dated on 2019-12-23: 20 Stocks Moving in Monday's Pre-Market Session

Financial news for PGNX dated on 2019-12-23: Progenics Pharmaceuticals shares are trading higher after the company announced the Phase 3 CONDOR trial on PyL in prostate cancer met the primary endpoint.

Financial news for PGNX dated on 2019-12-23: Progenics' Phase 3 CONDOR Trial of PyL Met its Primary Endpoint

Financial news for PGNX dated on 2019-12-23: Progenics Halted, News Pending

Financial news for PGNX dated on 2019-11-21: Progenics Pharma Names David Mims Interim CEO

Financial news for PGNX dated on 2019-11-11: Progenics Pharmaceuticals shares are trading lower. The company announced it has delivered written consents from the holders of more than 55% of the company's outstanding shares to remove CEO Mark Baker and Nicole Williams from the Board of Directors.

Financial news for PGNX dated on 2019-11-08: Velan Receives Requisite Number Of Written Consents To Reconstitute Majority Of Progenics Board

Financial news for PGNX dated on 2019-11-07: Progenics Pharmaceuticals Q3 EPS \$(0.22) Down From \$(0.01) YoY, Sales \$5.6M Up From \$5.317M YoY

Financial news for PGNX dated on 2019-11-04: Velan Capital Highlights Glass Lewis Recommendation Progenics Shareholders Vote On Green Consent Card For Velan Nominees

Financial news for PGNX dated on 2019-11-04: Progenics Issues Shareholder Letter Telling Shareholders To Reject Velan Capital's Board Nominees

Financial news for PGNX dated on 2019-10-28: Progenics Reports Strongly Agrees With ISS Recommendation Valen Group Shot Not Get Majority Control Of Board

Financial news for PGNX dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for PGNX dated on 2019-10-23: Velan Capital Issues Press Release Highlighting Response To 'Misleading Communications' From Progenics

Financial news for PGNX dated on 2019-10-23: Progenics Sends Letter To Shareholders, Highlights Added Concerns About Velan Capital

Financial news for PGNX dated on 2019-10-22: Velan Sends Progenics Pharmaceuticals Shareholders With New Plan And Independent Board Nominees, Criticizes Proposed Lantheus Transaction

Financial news for PGNX dated on 2019-10-21: Progenics Pharma Board Sends Letter To Shareholders, Urges Vote On WHITE Proxy Card

Financial news for PGNX dated on 2019-10-10: 35 Stocks Moving In Thursday's Mid-Day Session

Financial news for PGNX dated on 2019-10-09: Progenics Reports Will Send Letter To Shareholders Highlighting Belief In Value Which Will Be Created By Deal With Lantheus And Uncertainty Surrounding Velan Capital's Plan

Financial news for PGNX dated on 2019-10-07: Progenics Pharmaceuticals shares are trading lower. The stock is up over 8% in the past week and traders may potentially be taking profits.

Financial news for PGNX dated on 2019-10-07: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for PGNX dated on 2019-10-03: 46 Biggest Movers From Yesterday

Financial news for PGNX dated on 2019-10-02: Lantheus To Acquire Progenics Pharma In All-Stock Deal

Financial news for PGNX dated on 2019-10-02: Velan Comments On Announced Sale Of Progenics To Lantheus

Financial news for PGNX dated on 2019-10-02: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PGNX dated on 2019-10-02: 23 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PGNX dated on 2019-10-02: Lantheus To Acquire Progenics To Form Precision Diagnostics Imaging And Therapeutics Company; Progenics Shareholders To Receive 0.2502 Shares Of Lantheus Common Stock For Each Progenics Share

Financial news for PGNX dated on 2019-10-02: Progenics Pharmaceuticals Shares Resume Trade

Financial news for PGNX dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for PGNX dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for PGNX dated on 2019-09-18: Progenics Says Velan Capital Has Filed To Attempt To Gain Five Seats On Board

Financial news for PGNX dated on 2019-08-26: Altiva Management Says Continued To Engage With Progenics Pharmaceuticals With Hope Of Reaching A Mutual Resolution, Including Appointment Of New Directors; Progenics Board Has Been Unreceptive To Its Efforts To Reach A Resolution

Financial news for PGNX dated on 2019-08-23: 66 Biggest Movers From Yesterday

Financial news for PGNX dated on 2019-08-20: Stocks That Hit 52-Week Lows On Tuesday

Financial news for PGNX dated on 2019-08-16: The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission

Financial news for PGNX dated on 2019-08-13: 76 Biggest Movers From Yesterday

Financial news for PGNX dated on 2019-08-09: Progenics Pharmaceuticals Q2 EPS \$(0.23) Misses \$(0.19) Estimate, Sales \$9.966M Beat \$6.66M Estimate

Financial news for PGNX dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for PGNX dated on 2019-08-08: Progenics Pharmaceuticals Announces Board Accepts Resignations Of Directors Peter J. Crowley And Michael D. Kishbauch, Effective October 17, 2019

Financial news for PGNX dated on 2019-08-06: Progenics Pharmaceuticals Announces That The Centers For Medicare & Medicaid Services Has Approved Add-On Payment For AZEDRA

Financial news for PGNX dated on 2019-08-05: Progenics Pharmaceuticals Completes Enrollment In Pivotal Phase 3 CONDOR Study Of PyL For Detection Of Prostate Cancer

Financial news for PGNX dated on 2019-07-30: Benzinga's Top Upgrades, Downgrades For July 30, 2019

Financial news for PGNX dated on 2019-07-30: Brookline Capital Initiates Coverage On Progenics Pharmaceuticals with Buy Rating, Announces \$10 Price Target

Financial news for PGNX dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for PGNX dated on 2019-07-25: Progenics Pharma Highlights Collaboration With Veterans Affairs On AI Research Program For Medical Image Analysis, No Terms Disclosed

Financial news for PGNX dated on 2019-07-17: Bausch Health, Progenics Announce Court Upholds Validity and Determined Actavis' Infringement of Patent Protecting RELISTOR Tablets

Financial news for PGNX dated on 2019-07-17: Seeing Social Media Mention Of Progenics Prevailing In Relistor Patent Litigation

Financial news for PGNX dated on 2019-06-28: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

Financial news for PGNX dated on 2019-06-28: Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital

Financial news for PGNX dated on 2019-06-28: Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors

Financial news for PGNX dated on 2019-06-25: Velan Capital Urges Shareholders To Vote Against Re Election Of Certain Board Nominees

Financial news for PGNX dated on 2019-06-24: Progenics Says Independent Readers Using Co.'s PSMA AI Demonstrated Statistically Significant Improvement Of Accuracy, Speed, And Reproducibility Over Readers Without PSMA AI

Financial news for PGNX dated on 2019-06-24: Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan's Latest Inaccurate Claims

Financial news for PGNX dated on 2019-06-20: Progenics Pharmaceuticals To Initiate Basket Trial By Year End To Support Expanded Label For AZEDRA In Multiple MIBG Avid Neuroendocrine Tumors

Financial news for PGNX dated on 2019-06-19: Progenics Sends Letter To Shareholders Urging Vote For All Co. Directors On WHITE Proxy Card

Financial news for PGNX dated on 2019-06-18: Progenics Pharmaceuticals Announces Agreement With FUJIFILM Toyama Chemical Co. For Automated Bone Scan Index (aBSI) Product In Japan

Financial news for PGNX dated on 2019-06-17: Progenics Pharma Shareholder Velan Capital Makes a Statement to Shareholders

Financial news for PGNX dated on 2019-06-13: Progenics To Sends Letter To Shareholders, Urges Vote For WHITE Proxy Card

Financial news for PGNX dated on 2019-06-13: Progenics Pharma Reports Dosing Of First Patient With Phase 2 Study Of 1095 Radiotherapy for Treatment Of Metastatic Prostate Cancer

Financial news for PGNX dated on 2019-06-11: Progenics Shareholder, Velan Capital, Sends Letter To Shareholders Criticizing Board For Dilution, Urges Shareholders To Vote Against Re-Election Of Board Members

Financial news for PGNX dated on 2019-06-04: Progenics Shareholder, Velan Capital, Responds To 'Misleading' Statements From Co.; Expresses Concern With 'Misalignment' Of Interests With Progenics Stockholders

Financial news for PGNX dated on 2019-06-03: Progenics Highlights Presentation Of Updated Survival Data For AZEDRA In Advanced Pheochromocytoma And Paraganglioma; Patients Treated With AZEDRA Show Overall Survival Of 73.1% At Two Years And 44.2% At Four Years

Financial news for PGNX dated on 2019-05-14: Progenics Pharmaceuticals And ROTOP Pharmaka GmbH Announce European Collaboration For Prostate Cancer Imaging Agent 1404

Financial news for PGNX dated on 2019-05-09: Progenics Pharmaceuticals Q1 EPS \$(0.22) Misses \$(0.19) Estimate, Sales \$4.281M Beat \$4.15M Estimate

Financial news for PGNX dated on 2019-05-07: Progenics Pharmaceuticals Comments On Velan Capital's Preliminary Proxy Statement

Financial news for PGNX dated on 2019-05-06: Progenics Pharma Issues Statement Related To Velan Capital: Urges Shareholder To Vote For WHITE Proxy Card

Financial news for PGNX dated on 2019-05-06: Velan Capital Sends Letter To Progenics Pharma Board

Financial news for PGNX dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for PGNX dated on 2019-04-24: Progenics Highlights Publication Of Analysis Of PyL (18F-DCFPyL) In A Medical Journal

Financial news for PGNX dated on 2019-04-05: Progenics Pharma 13D Filing From Altiva Mgmt. Shows 6% Stake

Financial news for PGNX dated on 2019-03-14: Progenics Pharmaceuticals Q4 EPS \$(0.17) Misses \$(0.11) Estimate, Sales \$3.238M Down From \$3.889M YoY

Financial news for PGNX dated on 2019-03-14: The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

Financial news for PGNX dated on 2019-03-14: Progenics Reports Has Asserted Ownership Of Global Composition Of Matter Patent Filings Related To PSMA-617

Financial news for PGNX dated on 2019-03-11: Progenics Pharmaceuticals Announces Presentation Of Safety Data For AZEDRA At 2019 Endocrine Society (ENDO) Annual Meeting

Financial news for PGNX dated on 2019-02-11: Progenics Acquires Azedra Radiopharmaceutical Manufacturing Facility For \$8M

Financial news for PGNX dated on 2019-01-03: Curium, Progenics Announce European Collaboration for Prostate Cancer Imaging Agent PyL

Financial news for PGNX dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for PGNX dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for PGNX dated on 2018-12-13: 52 Biggest Movers From Yesterday

Financial news for PGNX dated on 2018-12-12: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PGNX dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for PGNX dated on 2018-12-10: Stocks Which Set New 52-Week Low The

Last Trading Session, Fri., Dec. 7, 2018

Financial news for PGNX dated on 2018-12-07: Credit Suisse Initiates Coverage On Progenics Pharmaceuticals with Outperform Rating, Announces \$6.50 Price Target

Financial news for PGNX dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for PGNX dated on 2018-12-03: Progenics Doses First Patient In Pivotal Phase 3 Study Of PyL, PSMA PET Imaging Agent, For The Detection Of Prostate Cancer

Financial news for PGNX dated on 2018-11-19: Progenics Pharma Says Will Present Safety, Tolerability Data From Pooled Analysis Of 4 Open-Label Phase 1, 2 Studies Of AZEDRA In Patients With Iobenguane Scan Positive Cancers At Radiological Society of North America Nov. 26, 2018

Financial news for PGNX dated on 2018-11-08: Progenics Pharmaceuticals Inc. Q3 EPS \$(0.30) Misses \$(0.18) Estimate, Sales \$5.32M Beat \$4.12M Estimate

Financial news for PGNX dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for PGNX dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for PGNX dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for PGNX dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for PGNX dated on 2018-10-11: Progenics Pharma Reports Advancement Of I-131 1095 For Treatment Of Metastatic Prostate Cancer Into Phase 2 Clinical Study

Financial news for PGNX dated on 2018-10-05: Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results'

Financial news for PGNX dated on 2018-10-05: Progenics Shares Resume Trade, Spike To High Of \$6.50, Up 6%, Pullback From High, Now Up 0.5%

Financial news for PGNX dated on 2018-10-05: Progenics Pharma Shares To Resume Trade At 8 a.m. EDT

Financial news for PGNX dated on 2018-10-05: UPDATE: Progenics Says 18F-DCFPyL 'Very Well' Tolerated, 7% Of Subjects Experienced At Least One Treatment-Related Adverse Event, But No Serious Adverse Events

Financial news for PGNX dated on 2018-10-05: Progenics Pharma Reports Results Of Phase 2/3 Trial Of PyL For Detection Of Prostate Cancer: First Co-Primary Endpoint Was Met, Second Co-Primary Endpoint Was Not Met

Financial news for PGNX dated on 2018-10-05: Progenics Pharma Shares Halted News Pending

Financial news for PGNX dated on 2018-09-14: 24 Stocks Moving In Friday's Pre-Market Session

Financial news for PGNX dated on 2018-09-14: 46 Biggest Movers From Yesterday

Financial news for PGNX dated on 2018-09-13: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for PGNX dated on 2018-09-13: Mid-Day Market Update: Crude Oil Down Over 2%; Progenics Pharmaceuticals Shares Plunge

Financial news for PGNX dated on 2018-09-13: Mid-Morning Market Update: Markets Open Higher; Kroger Sales Miss Views

Financial news for PGNX dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Financial news for PGNX dated on 2018-09-13: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for PGNX dated on 2018-09-12: 10 Stocks Moving In Wednesday's After-Hours Session

Financial news for PGNX dated on 2018-09-12: UPDATE: Progenics Pharmaceuticals CEO

Says Top Line Phase 3 Results Of 1404 Are Inconsistent With Phase 2 Data, Co. Conducting Thorough Analysis To Understand Outcome

Financial news for PGNX dated on 2018-09-12: Progenics Pharmaceuticals shares are down 17.7% after hours after Phase 3 data for cancer imaging agent 1404 did not meet co-primary endpoint of sensitivity.

Financial news for PGNX dated on 2018-09-12: Progenics Pharma Shares Resume Trade, Down 11.2%

Financial news for PGNX dated on 2018-09-12: Progenics Shares To Resume Trade At 4:30 p.m. EDT

Financial news for PGNX dated on 2018-09-12: Progenics Pharma Shares Halted News Pending

Financial news for PGNX dated on 2018-09-12: Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 Met Co-Primary Endpoint Of Specificity, Did Not Meet Endpoint Of Sensitivity

Financial news for PGNX dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for PGNX dated on 2018-08-09: 85 Biggest Movers From Yesterday

Financial news for PGNX dated on 2018-08-08: 68 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PGNX dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for PGNX dated on 2018-08-08: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PGNX dated on 2018-08-08: Progenics Pharmaceuticals Prices 9.09M Share Offering of Common Stock @\$8.25/Share

Financial news for PGNX dated on 2018-08-07: Progenics Pharmaceuticals Reports Proposed Public Offering of Common Stock

Financial news for PGNX dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for PGNX dated on 2018-08-06: Stocks Which Set New 52-Week Highs Friday, August 3rd

Financial news for PGNX dated on 2018-08-02: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for PGNX dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for PGNX dated on 2018-07-31: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jul. 31, 2018

Financial news for PGNX dated on 2018-07-31: Progenics Pharmaceuticals Q2 EPS \$(0.20) Up From \$(0.24) YoY, Sales \$3.88M Up From \$2.765M YoY

Financial news for PGNX dated on 2018-07-31: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PGNX dated on 2018-07-31: Progenics Pharma Shares Resume Trade, Up 15.6%

Financial news for PGNX dated on 2018-07-31: 50 Biggest Movers From Yesterday

Financial news for PGNX dated on 2018-07-31: Progenics Pharmaceuticals Announces FDA Approval for AZEDRA to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma

Financial news for PGNX dated on 2018-07-30: Press Release Confirms Progenics Pharma Receives FDA Approval For Azedra

Financial news for PGNX dated on 2018-07-30: Progenix Pharma Halt Code Changed From Volatility To T1, News Pending

Financial news for PGNX dated on 2018-07-30: UPDATE: FDA.gov Site Appears To Display Approval For Progenics Pharma's Azedra, For Which The Co. Had a PDUFA Date Set for Today

Financial news for PGNX dated on 2018-07-30: The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO

Financial news for PGNX dated on 2018-07-30: REMINDER: Progenix Pharma Has FDA PDUFA Date Today For Azedra

Financial news for PGNX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for PGNX dated on 2018-06-30: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for PGNX dated on 2018-06-26: Progenics Pharma Closes Enrollment Of Phase 2/3 Trial Of PSMA-Targeted PET/CT Imaging Agent PyL In Prostate Cancer

Financial news for PGNX dated on 2018-06-26: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PGNX dated on 2018-06-22: These 5 Stocks Are In Various Phases Of Downtrends Right Now

Financial news for PGNX dated on 2018-06-07: Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Financial news for PGNX dated on 2018-05-31: 8-K From Progenics Pharma Reports On May 25th Co. Entered a Settlement With Valeant and Salix Regarding Patent Infringement Case

Financial news for PGNX dated on 2018-05-09: Progenics Pharmaceuticals Q1 EPS \$(0.19) Beats \$(0.21) Estimate

Financial news for PGNX dated on 2018-03-26: 42 Biggest Movers From Friday

Financial news for PGNX dated on 2018-03-23: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for PGNX dated on 2018-03-23: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for PGNX dated on 2018-03-22: Progenics Pharmaceuticals Down 15-16% After FDA Extended Review Of New Drug Application For AZEDRA By Three Months

Financial news for PGNX dated on 2018-03-22: Progenics Pharma Reports 3-Month Extension Of PDUFA Date For AZEDRA To Jul. 30, 2018

Financial news for PGNX dated on 2018-03-13: Progenics Shares Up 3.8%, Stock Has Risen 17% Since Co. Announced Q4 Results March 8th; Co. Reported EPS \$(0.04) vs \$(0.10) In Same Qtr. Last Year, Sales \$3.889M vs \$4.652M YoY

Financial news for PGNX dated on 2018-03-13: Autodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This Week

Financial news for PGNX dated on 2018-03-09: 56 Biggest Movers From Yesterday

Financial news for PGNX dated on 2018-03-08: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for PGNX dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for PGNX dated on 2018-01-02: Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404

Financial news for PGNX dated on 2018-01-02: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PGNX dated on 2017-12-29: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for PGNX dated on 2017-12-29: Mid-Day Market Update: ADTRAN Drops On Weak Q4 Guidance; Atara Biotherapeutics Shares Spike Higher

Financial news for PGNX dated on 2017-12-29: Mid-Morning Market Update: Markets Edge Lower; MassRoots Is Going To Leverage Blockchain For The Cannabis Industry

Financial news for PGNX dated on 2017-12-29: Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA

Financial news for PGNX dated on 2017-11-02: Progenics Pharma Q3 EPS \$(0.22) vs \$(0.23) Est., Sales \$2.56M vs \$3.52M Est.

Financial news for PGNX dated on 2017-11-02: Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA in Pheochromocytoma and Paraganglioma

Financial news for PGNX dated on 2017-11-02: Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA(r) (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Financial news for PGNX dated on 2017-10-16: Progenics Pharmaceuticals Reports Presentations on AZEDRA and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine

Financial news for PGNX dated on 2017-09-18: 12 Biggest Mid-Day Gainers For Monday

Financial news for PGNX dated on 2017-09-01: 12 Biggest Mid-Day Losers For Friday

Financial news for PGNX dated on 2017-09-01: Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge

Financial news for PGNX dated on 2017-08-31: UPDATE: Progenics Says 'Manufacturer Has Requested Additional Time to Prepare for Pre-Approval Inspection of the Manufacturing Site'

Financial news for PGNX dated on 2017-08-31: Progenics Pharma Offers Update On Timing Of NDA Submission For AZEDRA: All Submissions Submitted Except For Notification Of Pre-Approval Inspection Readiness

Financial news for PGNX dated on 2017-08-28: Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge

Financial news for PGNX dated on 2017-08-09: Progenics Pharma Reports Q2 EPS \$(0.24) vs \$(0.21) Est., Sales \$2.765M vs \$3.7M Est.

Financial news for PGNX dated on 2017-07-18: Watching Valeant Shares Following Filing From Progenics Showing Paragraph IV Certification Notification For Certain Patents For Subcutaneous RELISTOR

Financial news for PGNX dated on 2017-07-18: 8-K From Progenics Pharma Shows Co. Received Notification Of Paragraph IV Certification For Certain Patents For Subcutaneous RELISTOR

Financial news for PGNX dated on 2017-07-12: Progenics Shares Could Double, According To Cantor

Financial news for PGNX dated on 2017-07-12: Benzinga's Top Upgrades, Downgrades For July 12, 2017

Financial news for PGNX dated on 2017-07-12: Cantor Fitzgerald Initiates Coverage On Progenics Pharmaceuticals with Overweight Rating, Announces \$15.00 Price Target

Financial news for PGNX dated on 2017-05-05: Mid-Morning Market Update: Markets Open Mixed; Cognizant Earnings Beat Views

Financial news for PGNX dated on 2017-05-04: Progenics Pharmaceuticals Reports Q1 EPS \$(0.23) vs \$(0.19) Est., Sales \$2.34M vs \$4.4M Est.

Financial news for PGNX dated on 2017-04-03: Exclusive: Progenics CEO Talks Regulatory Climate, Positive Trials For Ultra-Orphan Azedra

Financial news for PGNX dated on 2017-03-30: Progenics Pharma Reports Topline Results from Registrational Phase 2b Trial of AZEDRA: Achieved Primary Endpoint

Financial news for PGNX dated on 2017-03-28: Watch These 10 Huge Call Purchases In Tuesday Trade

Financial news for PGNX dated on 2017-03-27: Benzinga's Option Alert Recap From March 27

Financial news for PGNX dated on 2017-03-27: Option Alert: Progenics Pharma May 11.0 Calls Sweep: 500 @ ASK \$1.10: 500 traded vs 1387 OI: Earnings 5/4 Before Open (est) \$10.98 Ref

Financial news for PGNX dated on 2017-03-24: Benzinga's Option Alert Recap From March 24

Financial news for PGNX dated on 2017-03-24: Option Alert: Progenics Pharma Apr 11.0 Calls: 550 @ ASK \$1.15: 1023 traded vs 1809 OI: Earnings 5/4 Before Open (est)



\$11.23 Ref

Financial news for PGNX dated on 2017-03-09: Progenics Pharmaceuticals Reports Q4 EPS \$(0.10) vs. \$(0.20) Est., Sales \$4.65M vs. \$4.81M Est.

Financial news for PGNX dated on 2017-02-15: S&P Dow Jones Indices Reports Progenics Pharma, Shutterfly to Join S&P SmallCap 600

Financial news for PGNX dated on 2017-02-15: Watch These 5 Huge Put Purchases In Wednesday Trade

Financial news for PGNX dated on 2017-02-14: Option Alert: Progenics May 10.0 Puts Sweep: 500 @ ASK \$1.60: 500 traded vs 62 OI: Earnings 3/9 Before Open (est) \$9.52 Ref

Financial news for PGNX dated on 2017-02-14: Progenics Reports Initiation of Phase 1 Trial of 1095 for Treatment of Metastatic Prostate Cancer

Financial news for PGNX dated on 2017-02-06: 7 Biggest Price Target Changes For Monday

Financial news for PGNX dated on 2017-02-06: Needham Upgrades Progenics Pharmaceuticals To Strong Buy, Raises Price Target To \$14

Financial news for PGNX dated on 2017-01-09: Progenics Pharma Files \$250M Mixed Shelf

Financial news for PGNX dated on 2016-12-22: UPDATE: Progenics Says A Modification To Its Phase 3 SPECT/CT Trial Protocol Has Been Proposed To And Accepted By The FDA

Financial news for PGNX dated on 2016-12-22: Progenics Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT

Financial news for PGNX dated on 2016-12-07: Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL

Financial news for PGNX dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for PGNX dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for PGNX dated on 2016-11-07: Progenics Pharma Reports Q3 EPS \$0.52 vs \$0.55 Est., Sales \$53.85M vs \$52.9M Est.

Financial news for PGNX dated on 2016-11-07: Progenics Pharma Reports \$50M RELISTOR Royalty-Backed Financing

Financial news for PGNX dated on 2016-10-28: Progenics Pharmaceuticals Received Notification Of Paragraph IV Certification For Certain Patents On Relistor Tablets, Listed In FDA's Orange Book

Financial news for PGNX dated on 2016-10-27: Benzinga's Top Initiations

Financial news for PGNX dated on 2016-10-27: Aegis Capital Initiates Coverage On Progenics Pharmaceuticals Inc. - Common Stock at Buy, Announces \$11.00

Financial news for PGNX dated on 2016-10-05: 17 Stocks Which Rallied Three Days On Increasing Volume

Financial news for PGNX dated on 2016-10-04: Brean Capital Assumes Progenics Pharmaceuticals at Buy, Announces \$11.00 PT

Financial news for PGNX dated on 2016-09-09: UPDATE: Also Watching Seres, Protagonist Therapeutics, Progenics Following Breaking 911 Report on 'Newest superbug'; Shares Not Reacting

Financial news for PGNX dated on 2016-09-07: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for PGNX dated on 2016-09-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PGNX dated on 2016-09-06: Progenics Spikes to High of \$6.97 After-Hours on Relistor News

Financial news for PGNX dated on 2016-09-06: Valeant, Progenics Reports The U.S.

## Commercial Launch Of FDA-Approved Relistor Tablets

Financial news for PGNX dated on 2016-08-25: Watch These 7 Huge Put Purchases In Thursday Trade

Financial news for PGNX dated on 2016-08-24: Option Alert: PGNX Oct16 6.0 Puts Sweep: 500 @ ASK \$0.30: 500 traded vs 0 OI: \$6.65 Ref

Financial news for PGNX dated on 2016-08-04: Progenics Pharmaceuticals Reports Q2 EPS \$(0.08) vs. Est. \$(0.13), Rev. \$8.47M vs. Est. \$6.33M

Financial news for PGNX dated on 2016-07-26: UPDATE: Progenics Also Entitled to Receive Up to \$200M of Sales Milestone Payments Based on Specified US Sales Targets

Financial news for PGNX dated on 2016-07-26: Progenics Receives \$50 Million Milestone Payment Following FDA Approval of RELISTOR

Financial news for PGNX dated on 2016-07-20: Mid-Afternoon Market Update: NASDAQ Up Over 1%; Cintas Shares Surge On Upbeat Earnings

Financial news for PGNX dated on 2016-07-20: Technical Alert - Progenics Pharmaceuticals Peaks At Mid-December Highs

Financial news for PGNX dated on 2016-07-20: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for PGNX dated on 2016-07-20: Mid-Day Market Update: Microsoft Gains Following Earnings Beat; Zafgen Shares Slide

Financial news for PGNX dated on 2016-07-20: Option Alert: PGNX 11500 Aug \$6 Call at Bid @\$0.55

Financial news for PGNX dated on 2016-07-20: Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q2 Estimates

Financial news for PGNX dated on 2016-07-20: 15 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PGNX dated on 2016-07-20: Progenics Pharmaceuticals +33% Preamarket @\$6.59; Co Announced FDA Approval of Relistor Tablets for Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Financial news for PGNX dated on 2016-07-19: Progenics Pharmaceuticals Resumes Trading; High of \$6.50 +29%

Financial news for PGNX dated on 2016-07-19: Progenics Pharmaceuticals to Resume Trading at 6:25 PM ET

Financial news for PGNX dated on 2016-07-19: Progenics Pharmaceuticals, Inc. Shares Up 11% At \$5.49/Share After Hours

Financial news for PGNX dated on 2016-07-19: Valeant, Progenics Reports FDA Approves RELISTOR Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Financial news for PGNX dated on 2016-07-14: Progenics Pharma Sells off to Low of \$4.84 on Vol

Financial news for PGNX dated on 2016-06-21: Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Financial news for PGNX dated on 2016-05-02: Progenics Licenses PSMA Antibody Technology to Bayer; Progenics to Receive Upfront Fee Plus Additional Potential Clinical and Regulatory Development Milestones

Financial news for PGNX dated on 2016-04-04: Valeant, Progenics Reports PDUFA Date Extension for Oral RELISTOR; Extended To July 19, 2016

Financial news for PGNX dated on 2016-03-17: Option Alert: PGNX Apr16 3.0 Puts: 500 @ ASK \$0.05: 500 traded vs 0 OI: Earnings 5/4 \$3.92 Ref

Financial news for PGNX dated on 2016-03-11: Progenics Pharma. Reports Q4 EPS \$(0.10) vs. Prior Year Quarter \$(0.18)

Financial news for PGNX dated on 2016-03-11: Earnings Scheduled For March 11, 2016

Financial news for PGNX dated on 2016-02-10: Mid-Day Market Update: Akamai Technologies Surges On Earnings Beat; KapStone Paper and Packaging Shares Drop

Financial news for PGNX dated on 2016-01-12: Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside

Financial news for PGNX dated on 2016-01-07: Progenics Pharma Reports Commencement of Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer

Financial news for PGNX dated on 2015-12-11: 16 Stocks Moving In Friday's After-Hours Session

Financial news for PGNX dated on 2015-12-03: Progenics Pharmaceuticals Reaches Target Enrollment in its Phase 2b Pivotal Trial of Azedra

Financial news for PGNX dated on 2015-11-09: Progenics Pharma Reports Q3 EPS (\$0.14) Vs Est (\$0.13), Sales \$1.4M Vs Est \$2.35M

Financial news for PGNX dated on 2015-10-23: Benzinga's Top Upgrades

Financial news for PGNX dated on 2015-10-23: Jefferies Upgrades Progenics Pharmaceuticals to Buy, Raises PT to \$9.00

Financial news for PGNX dated on 2015-10-13: Progenics Pharma 8-K Says Company Received Notice Of Paragraph IV Certification For Certain Patents For RELISTOR On Oct 7

Financial news for PGNX dated on 2015-10-13: Progenics Announces Offer to Acquire EXINI, \$7M Cash

Financial news for PGNX dated on 2015-10-13: Progenics Pharmaceuticals Announces Tender Offer for Exini for 3.15 Swedish Crowns/Share -Reuters

Financial news for PGNX dated on 2015-10-12: Data From Phase 2 Study of Progenics' 1404 Imaging Agent Presented at EANM Congress 2015

Financial news for PGNX dated on 2015-09-08: Valeant, Progenics Report FDA Acceptance Of NDA Submission For Oral RELISTOR

Financial news for PGNX dated on 2015-08-06: Progenics Pharma Reports Q2 Loss of \$0.17/Share vs Loss of \$0.14/Share Est., Sales \$1.9M vs \$1.63M Est.

Financial news for PGNX dated on 2015-08-04: Progenics Pharmaceuticals Reports Exclusive Worldwide Licensing Agreement With Johns Hopkins University for Agent to Image Prostate Cancer Using PET Scan

Financial news for PGNX dated on 2015-07-28: Mid-Morning Market Update: Markets Rise; Ford Beats Q2 Estimates

Financial news for PGNX dated on 2015-07-28: Stocks Hitting 52-Week Highs

Financial news for PGNX dated on 2015-07-28: Morning Market Gainers

Financial news for PGNX dated on 2015-07-28: Azedra Designated as Breakthrough Therapy for Iobenguane-Avid Metastatic or Recurrent Pheochromocytoma and Paraganglioma, Received Orphan Drug And Fast Track Designations From FDA

Financial news for PGNX dated on 2015-07-07: Progenics Pharmaceuticals Reports Plans to Move Forward With 1404 Phase 3 Trial; Expects Trial To Commence By End of Year

Financial news for PGNX dated on 2015-06-25: Needham Is Bullish On Progenics Pharmaceuticals

Financial news for PGNX dated on 2015-06-23: Valeant and Progenics Submit U.S. New Drug Application for Oral RELISTOR

Financial news for PGNX dated on 2015-06-22: UPDATE: Progenics Shares +27%

Financial news for PGNX dated on 2015-06-22: Progenics Pharma Shares Spike to New High

Financial news for PGNX dated on 2015-06-03: Valeant Product Producer Progenics Announce European Approval For RELISTOR To Treat All Opioid Induced Constipation

Financial news for PGNX dated on 2015-05-27: BTIG Research Initiates Coverage on Progenics Pharmaceuticals at Buy, Announces \$12.00 PT

Financial news for PGNX dated on 2015-05-06: Progenic Pharma Reports Q1 EPS Loss \$0.15 Vs Est Loss \$0.16

Financial news for PGNX dated on 2015-04-07: Progenics Announces the Start of Fuji's Phase 2 Trial for 1404 in Japan

Financial news for PGNX dated on 2015-03-16: Progenics Pharma Reports Q4 EPS -\$0.18 Vs Est -\$0.13

Financial news for PGNX dated on 2015-03-16: Earnings Scheduled For March 16, 2015

Financial news for PGNX dated on 2015-02-26: UPDATE: Progenics Says Data from Trial Provides Compelling Evidence of Anti-Cancer Properties of PSMA ADC"

Financial news for PGNX dated on 2015-01-23: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA

Financial news for PGNX dated on 2014-11-07: Morning Market Movers

Financial news for PGNX dated on 2014-11-07: Progenics Shares Rise 19% Premarket on Much Better than Expected Earnings Report

Financial news for PGNX dated on 2014-11-07: Progenics Pharmaceuticals Inc. Reports Q3 EPS of \$0.51; Revenue of \$41.70M

Financial news for PGNX dated on 2014-11-07: Earnings Scheduled For November 7, 2014

Financial news for PGNX dated on 2014-10-20: Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

Financial news for PGNX dated on 2014-10-16: UPDATE: Progenics Shares Rise 25% Following CNBC Mention

Financial news for PGNX dated on 2014-10-16: Progenix Mentioned on CNBC as Ebola Play

Financial news for PGNX dated on 2014-10-06: Progenics Receives \$40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic Non-Cancer Pain

Financial news for PGNX dated on 2014-09-30: Morning Market Losers

Financial news for PGNX dated on 2014-09-29: Progenics Shares Resume Trading, Now Up 3.5%

Financial news for PGNX dated on 2014-09-29: UPDATE: Salix, Progenics Report FDA Okay of RELISTOR

Financial news for PGNX dated on 2014-09-29: Salix, Progenics Report FDA Okay of RELISTOR

Financial news for PGNX dated on 2014-09-29: Shares of Progenics Halted News Pending

Financial news for PGNX dated on 2014-09-23: Jefferies Initiates Coverage on Progenics Pharmaceuticals Inc. at Hold, Announces \$6.00 PT

Financial news for PGNX dated on 2014-08-11: US Stock Futures Signal Higher Start On Wall Street

Financial news for PGNX dated on 2014-08-11: FDA Assigns September 29, 2014 PDUFA Goal Date for RELISTOR Subcutaneous Injection sNDA

Financial news for PGNX dated on 2014-08-08: Progenics Pharmaceuticals Inc. Reports Q2 EPS of \$(0.17) vs \$(0.14) Est; Revenue of \$1.48M vs \$2.83M Est

Financial news for PGNX dated on 2014-08-08: Earnings Scheduled For August 8, 2014

Financial news for PGNX dated on 2014-07-14: Morning Market Movers

Financial news for PGNX dated on 2014-07-14: Benzinga's Top #PreMarket Gainers

Financial news for PGNX dated on 2014-07-14: Progenics Pharma Shares up ~18%

Financial news for PGNX dated on 2014-07-14: US Stock Futures Surge; All Eyes On Citigroup Results

Financial news for PGNX dated on 2014-07-14: PREVIEW: Progenics Pharmaceuticals to Resume Trading at 7:30 AM ET

Financial news for PGNX dated on 2014-07-14: UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA Approval Of RELISTOR sNDA

Financial news for PGNX dated on 2014-07-14: Progenics Announces Will Host Call Related to FDA Appeal Response Related to RELISTOR sNDA

Financial news for PGNX dated on 2014-07-14: Salix, Progenics Report FDA Office of Drug Evaluation III Approves Salix Request for FDA Approval of RELISTOR sNDA

Financial news for PGNX dated on 2014-07-14: Progenics Pharmaceuticals Halted; Pending News

Financial news for PGNX dated on 2014-06-12: Shares of Progenics Resume Trade, Now Up Nearly 19%

Financial news for PGNX dated on 2014-06-12: Shares of Progenics to Resume Trade at 3:15 p.m. EDT

Financial news for PGNX dated on 2014-06-12: Sucampo Says FDA Did Not Require Company To Reevaluate Clinical Data Because Action Mechanism For Opioid Constipation is Different

Financial news for PGNX dated on 2014-06-12: Salix Pharma, Progenics Pharma Report on FDA Advisory Panel Recommendations, 12 Members Voted Not to Require CVOT Trial, Seven Vote to Require CVOT for Pamorsia

Financial news for PGNX dated on 2014-06-12: Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

Financial news for PGNX dated on 2014-06-11: UPDATE: Nektar Therapeutics, Progenics Halted for FDA Advisory Committees

Financial news for PGNX dated on 2014-06-11: Nektar Therapeutics, Progenics Halted: Pending News

Financial news for PGNX dated on 2014-06-09: Small Pharmaceuticals Rallying Following FDA Report

Financial news for PGNX dated on 2014-06-06: Mid-Afternoon Market Update; Hertz Down, QuikSilver Gain On CEO & CFO Share Purchases

Financial news for PGNX dated on 2014-06-06: Mid-Day Market Update: Diamond Foods Shares Fall After Weak Earnings; GW Pharma Gains

Financial news for PGNX dated on 2014-05-09: Progenics Pharmaceuticals Inc. Reports Q1 EPS of \$(0.15), Inline; Revenue of \$1.82M vs \$2.88M Est

Financial news for PGNX dated on 2014-05-09: Earnings Scheduled For May 9, 2014

Financial news for PGNX dated on 2014-04-24: Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

Financial news for PGNX dated on 2014-04-22: US Stock Futures Edge Higher Ahead Of McDonald's Earnings

Financial news for PGNX dated on 2014-04-22: Salix Pharma, Progenics Reports Acceptance of Submission for Expanded Use of RELISTOR in Chronic Non-Cancer Pain by EMA

Financial news for PGNX dated on 2014-04-22: Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand Use of RELISTOR by the European Medicines Agency

Financial news for PGNX dated on 2014-03-13: Progenics Pharmaceuticals Inc. Reports Q4 EPS of \$(0.14) vs \$(0.19) Est; Revenue of \$2.97M vs \$1.48M Est

Financial news for PGNX dated on 2014-03-13: Earnings Scheduled For March 13, 2014

Financial news for PGNX dated on 2014-02-21: Progenics Prices 7.61M Shares at \$4.60/Share, Expecting Gross Proceeds \$35M

Financial news for PGNX dated on 2014-02-06: Option Alert: Progenics Mar \$6 Call; 3,078 Contracts Traded vs 697 OI; Currently \$4.55

Financial news for PGNX dated on 2014-02-06: Bloomberg Reporting Progenix, Salix Informed by FDA That ADPAC Meeting Postponed; FDA Cited Scheduling Conflicts

Financial news for PGNX dated on 2014-02-03: Needham Upgrades Progenics Pharmaceuticals Inc. to Buy, Announces \$8.00 PT

Financial news for PGNX dated on 2014-01-30: UPDATE: Progenics Shares Rise 19% on Positive Phase 2 Study Results

Financial news for PGNX dated on 2014-01-30: Progenics 1404 Imaging Agent Shows High Accuracy in Detecting Cancer Within the Prostate Gland in Interim Analysis of Phase 2

## Study

Financial news for PGNX dated on 2014-01-30: Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer

Financial news for PGNX dated on 2014-01-29: Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors

Financial news for PGNX dated on 2014-01-29: Option Alert: Progenics Pharmaceuticals Feb \$5 Call; 1,671 Contract Trade Between Bid and Ask @\$0.50; Currently \$4.58

Financial news for PGNX dated on 2013-11-25: Progenics Pharmaceuticals Relaunches Registrational Trial of Azedra to Treat Pheochromocytomas

Financial news for PGNX dated on 2013-11-11: Progenics Pharmaceuticals Inc. Reports Q3 EPS of \$(0.17) vs \$(0.22) Est; Revenue of \$867.0K vs \$2.0M Est

Financial news for PGNX dated on 2013-11-11: Earnings Scheduled For November 11, 2013

Financial news for PGNX dated on 2013-10-01: Salix Says FDA Scheduled to Review Relistor SNDA March 10-11

Financial news for PGNX dated on 2013-08-09: Progenics Pharmaceuticals Inc. Reports Q2 EPS of \$(0.24), Inline; Revenue of \$1.80M vs \$1.86M Est

Financial news for PGNX dated on 2013-07-08: Afternoon Market Gainers

Financial news for PGNX dated on 2013-07-08: Brean Capital Upgrades Progenics Pharmaceuticals Inc. to Buy, Announces \$9.00 PT

Financial news for PGNX dated on 2013-06-25: Form 8-K from Progenics Pharma Shows Co. Closed 8.5M Primary Share Offering

Financial news for PGNX dated on 2013-06-20: Progenics Prices 8.5M Shares at \$4.40/Share for Gross Proceeds \$37.4M

Financial news for PGNX dated on 2013-06-19: Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for PGNX dated on 2013-06-11: Afternoon Market Gainers

Financial news for PGNX dated on 2013-06-11: Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain

Financial news for PGNX dated on 2013-06-10: Afternoon Market Losers

Financial news for PGNX dated on 2013-06-01: Progenics Pharmaceuticals' Presents Data from Phase 1 Study of PSMA ADC

Financial news for PGNX dated on 2013-05-10: Progenics Pharmaceuticals Inc. Reports Q1 EPS of \$(0.22) vs \$(0.19) Est; Revenue of \$2.23M vs \$1.71M Est

Financial news for PGNX dated on 2013-05-10: Earnings Scheduled For May 10, 2013

Financial news for PGNX dated on 2013-03-17: Benzinga's Small Cap Movers for Friday March 15, 2013

Financial news for PGNX dated on 2013-03-15: Market Wrap for Friday, March 15: Dow Snaps Winning Streak; Stocks Record Minor Losses

Financial news for PGNX dated on 2013-03-15: Unusual Options Activity: Progenics Pharmaceuticals May \$4.00 At-The-Money Puts Trade 5,170 Times Against an Open Interest of 8 After Company Reported Earnings This Morning

Financial news for PGNX dated on 2013-03-15: Progenics Pharmaceuticals Inc. Reports Q4 EPS of \$(0.01) Which May Not Compare \$(0.31) Est; Revenue of \$8.89M Which May Not Compare \$1.16M Est

Financial news for PGNX dated on 2013-03-15: Earnings Scheduled For March 15, 2013

Financial news for PGNX dated on 2012-12-21: Stocks on my Watch List for Friday, December 21

Financial news for PGNX dated on 2012-12-20: Top Stocks on my Watch List for Thursday December 20th

Financial news for PGNX dated on 2012-11-29: Progenics Pharma Says 11M Shares Priced

at \$2/Share

Financial news for PGNX dated on 2012-09-28: Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients

Financial news for PGNX dated on 2012-09-20: Progenics Pharma Cutting 26% of Jobs, CFO Stepping Down

Financial news for PGNX dated on 2012-08-30: Stifel Nicolaus Initiates Coverage on Progenics Pharmaceuticals at Hold

Financial news for PGNX dated on 2012-08-09: Progenics Pharmaceuticals Reports Q2 EPS \$-0.32 vs \$-0.32 Est; Revenues \$1.82M vs \$2.61M Est

Financial news for PGNX dated on 2012-08-09: Progenics Pharmaceuticals Reports Q2 EPS \$-0.32 vs \$-0.32 Est; Revenues \$1.82M vs \$2.61M Est

Financial news for PGNX dated on 2012-07-30: Benzinga's Top Pre-Market Losers

Financial news for PGNX dated on 2012-07-30: Financial Breakfast: Morning News Summary for July 30, 2012

Financial news for PGNX dated on 2012-07-30: Salix Pharmaceuticals Falls 15%, Progenics Falls 40% Pre-Market Following Receipt of CRL from FDA

Financial news for PGNX dated on 2012-07-30: Friday, Salix and Progenics Receive Complete Response Letter from FDA for RELISTOR(R) sNDA; FDA Requests More Data

Financial news for PGNX dated on 2012-03-15: Brean Murray Carret & Co. Maintains Progenics Pharmaceuticals at Buy, Raises PT from \$13 to \$14

Financial news for PGNX dated on 2011-12-21: Investor Ideas' Tuesday's NASDAQ Winners

Financial news for PGNX dated on 2011-12-20: Microcap Movers for Tuesday December 20, 2011

Financial news for PGNX dated on 2011-12-20: Progenics Pharma Up 30% on Positive Phase 3 Results

Financial news for PGNX dated on 2011-12-20: Notable Call Options Activity in Progenics Pharmaceuticals

Financial news for PGNX dated on 2011-12-20: Morning Market Movers

Financial news for PGNX dated on 2011-12-20: Financial Breakfast: Morning News Summary for December 20, 2011

Financial news for PGNX dated on 2011-12-20: Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic

Financial news for PGNX dated on 2011-12-11: Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)

Financial news for PGNX dated on 2011-12-07: Notable Call Options Activity in Progenics Pharmaceuticals

Financial news for PGNX dated on 2011-09-15: Progenics Pharmaceuticals Announces Strategic Focus on Oncology

Financial news for PGNX dated on 2011-08-30: Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR in Patients with Non-Cancer Pain

Financial news for PGNX dated on 2011-08-11: Progenics Pharm Files \$100 Mixed Securities Shelf

Financial news for PGNX dated on 2011-05-20: Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients

Financial news for PGNX dated on 2011-04-14: Progenics Pharmaceuticals Hits 52-Week High (PGNX)

Financial news for PGNX dated on 2011-03-15: Progenics Pharmaceuticals Reports Q4 EPS of \$(0.57) vs. \$(0.57)

Financial news for PGNX dated on 2011-02-17: Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC

Financial news for PGNX dated on 2011-02-10: Benzinga's Top Pre-Market NASDAQ Gainers

(WFMI, PGNX, SQNM, XNPT)

Financial news for PGNX dated on 2011-02-07: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, PGNX, GOLD, GENZ)

Financial news for PGNX dated on 2010-12-23: Progenics Pharmaceuticals Climbs 5.9% (PGNX)

Financial news for PGNX dated on 2010-11-08: Progenics Pharmaceuticals Announces Third Quarter EPS of \$(0.52)

Financial news for PGNX dated on 2010-10-06: Progenics Awarded \$4.1 Million NIH Grant

Financial news for PGNX dated on 2010-09-22: Traders Bullish on Progenics Pharma (PGNX)

Financial news for PGNX dated on 2010-09-13: Oppenheimer's Current Biotech Ratings

Financial news for PGNX dated on 2010-08-12: Trade Like Hedge Fund Billionaire Paul Tudor Jones (EEM, FXI, MJN, PGNX, RSX, XLP)

Financial news for PGNX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?